Goldenwell Biotech (GWLL) Return on Capital Employed (2021 - 2025)

Goldenwell Biotech has reported Return on Capital Employed for 4 years, with the latest figure at 28.47% in Q3 2025.

• For the quarter ending Q3 2025, Return on Capital Employed changed N/A year-over-year to 28.47%; the trailing twelve-month figure through Sep 2025 stood at 28.47% (changed N/A YoY), and the FY2024 full-year result was 12.3%, changed N/A from the prior year.
• Return on Capital Employed for Q3 2025 stood at 28.47%, up from 25.99% in the prior quarter.
• The five-year high for Return on Capital Employed was 28.47% in Q3 2025, with the low at 60.1% in Q2 2022.
• Historically, Return on Capital Employed has averaged 9.88% across 4 years, with a median of 6.08% in 2021.
• The largest YoY upside for Return on Capital Employed was 2488 bps in 2022 against a maximum downside of 2488 bps in 2022.
• Goldenwell Biotech's Return on Capital Employed stood at 7.45% in 2021, then sank by 297 bps to 29.58% in 2022, then jumped by 95 bps to 1.57% in 2024, then surged by 1912 bps to 28.47% in 2025.
• The last three Return on Capital Employed figures came in at 28.47% (Q3 2025), 25.99% (Q2 2025), and 1.57% (Q4 2024), per Business Quant data.